Effectiveness of vitiligo therapy in prospective observational study of 250 cases with review of consensus and individualized care pers
Keywords:
Vitiligo, pharmacotherapy, therapeutic guidelines, observational studyAbstract
Patients and methods Outcomes of six month therapy in 250 patients bearing varying disease profiles and treatment regimens delivered either in conformity or divergence from consensus guidelines were compared. Influence of trait variables of patients and disease on the outcomes was also examined. Results Consensus approach yielded superior rates of repigmentation and improved quality of life. The latter effect significantly influenced the former. Therapy adhering guidelines did not yield optimal benefit in patients of younger age, with disease of shorter standing and involving resistant sites. Steroids best benefited the localized disease as topical monotherapy. Combination of steroid with photochemotherapy adhering guidelines benefited less in moderate disease extent. Steroid overtreatment in extensive disease compromised the prospects of repigmentation. Conclusions Localized short duration disease may better be first treated with steroid-alternative immunosuppressants. Wider spread more than 3% body surface may also respond to their combination with steroids, prior applying photochemotherapy. Additive therapies are prudent with steroid/photochemotherapy than injudicious steroid overuse in progressive extensive disease. Strategies to counter steroid unresponsiveness and adverse effects, psychiatric address to stress, nutrient and environmental interventions deserve emphasis.References
Felsten LM, Alikhan A, Petronic-Rosic V. Vitiligo: a comprehensive overview Part II: treatment options and approach to treatment. J Am Acad Dermatol. 2011;65:493-514.
Gawkrodger DJ, Ormerod AD, Shaw L et al. Therapy Guidelines and Audit Subcommittee, British Association of Dermatologists; Clinical Standards Department, Royal College of Physicians of London; Cochrane Skin Group; Vitiligo Society. Guideline for the diagnosis and management of vitiligo. Br J Dermatol. 2008;159:1051-76.
Gawkrodger DJ, Ormerod AD, Shaw L et al. Vitiligo: concise evidence based guidelines on diagnosis and management. Postgrad Med J. 2010;86:466-71.
Nordlund JJ. Vitiligo: a review of some facts lesser known about depigmentation. Indian J Dermatol. 2011;56:180-9.
Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65:473-91.
Slominski A, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev. 2004;84:1155-228.
Norris DA, Kissinger RM, Naughton GM, Bystryn JC. Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol. 1988;90:783-9.
Dell’anna ML, Picardo M. A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. Pigment Cell Res. 2006;19:406-11.
Hasse S, Gibbons NC, Rokos H et al. Perturbed 6-tetrahydrobiopterin recycling via decreased dihydropteridine reductase in vitiligo: more evidence for H2O2 stress. J Invest Dermatol. 2004;122:307-13.
Lee AY, Kim NH, Choi WI, Youm YH. Less keratinocyte-derived factors related to more keratinocyte apoptosis in depigmented than normally pigmented suction-blistered epidermis may cause passive melanocyte death in vitiligo. J Invest Dermatol. 2005;124:976-83.
Lotti T, Gori A, Zanieri F et al. Vitiligo: new and emerging treatments. Dermatol Ther. 2008;21:110-7.
Gokhale BB, Mehta LN. Histopathology of vitiliginous skin. Int J Dermatol. 1983;22:477-80.
Das SK, Majumder PP, Chakraborty R et al. Studies on vitiligo. I. Epidemiological profile in Calcutta, India. Genet Epidemiol. 1985;2:71-8.
Sehgal VN, Srivastava G. Vitiligo: compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol. 2007;73:149-56.
Cheah TS. The impact of clinical guidelines and clinical pathways on medical practice: effectiveness and medico-legal aspects. Ann Acad Med Singapore. 1998;27:533-9.
Handa S, Pandhi R, Kaur I. Vitiligo: a retrospective comparative analysis of treatment modalities in 500 patients. J Dermatol. 2001;28:461-6.
Thappa DM. Vitiligo. Indian J Dermatol Venereol Leprol. 2002;68:227-8.
Hamzavi I, Jain H, McLean D et al. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol. 2004;140:677-83.
Taïeb A, Picardo M. Clinical practice. Vitiligo. N Engl J Med. 2009;360:160-9.
Kawakami T, Hashimoto T. Disease severity indexes and treatment evaluation criteria in vitiligo. Dermatol Res Pract. 2011;2011:750342. doi: 10.1155/2011/750342
Jose RM, Roy DK, Vidyadharan R, Erdmann M. Burns area estimation-an error perpetuated. Burns. 2004;30:481-2.
Ramsay B, Lawrence CM. Measurement of involved surface area in patients with psoriasis. Br J Dermatol. 1991;124:565-70.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210-6.
Mulekar SV, Al Issa A, Asaad M et al. Mixed vitiligo. J Cutan Med Surg. 2006;10:104-7.
Lee DY, Lee KJ, Choi SC, Lee JH. Segmental vitiligo treated by the combination of epidermal grafting and systemic corticosteroids. Dermatol Surg. 2010;36:575-6.
Dave S, Thappa DM, Dsouza M. Clinical predictors of outcome in vitiligo. Indian J Dermatol Venereol Leprol 2002;68:323-5.
Huang CL, Nordlund JJ, Boissy R. Vitiligo: a manifestation of apoptosis? Am J Clin Dermatol. 2002;3:301-8.
Falabella R. Vitiligo and the melanocyte reservoir. Indian J Dermatol. 2009;54:313-8.
Attili VR, Attili SK. Lichenoid inflammation in vitiligo -a clinical and histopathologic review of 210 cases. Int J Dermatol. 2008;47:663-9.
Shin JW, Nam KM, Choi HR et al. Erythrocyte malondialdehyde and glutathione levels in vitiligo patients. Ann Dermatol. 2010;22:279-83.
Birlea SA, Costin GE, Norris DA. Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets. 2008;9:345-59.
Ameen M, Exarchou V, Chu AC. Topical calcipotriol as monotherapy and in combination with psoralen plus ultraviolet A in the treatment of vitiligo. Br J Dermatol. 2001;145:476-9.
Xu AE, Zhang DM, Wei XD et al. Efficacy and safety of tacrolimus cream 0.1% in the treatment of vitiligo. Int J Dermatol. 2009;48:86-90.
Radoja N, Komine M, Jho SH et al. Novel mechanism of steroid action in skin through glucocorticoid receptor monomers. Mol Cell Biol. 2000;20:4328-39.
Ndlovu MN, Denis H, Fuks F. Exposing the DNA methylome iceberg. Trends Biochem Sci. 2011;36:381-7.
Libetta C, Sepe V, Zucchi M et al. Influence of methylprednisolone on plasma homocysteine levels in cadaveric renal transplant recipients. Transplant Proc. 2006;38:2893-4.
Kao JS, Fluhr JW, Man MQ et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol. 2003;120:456-64.
Schallreuter KU, Chavan B, Rokos H et al. Decreased phenylalanine uptake and turnover in patients with vitiligo. Mol Genet Metab. 2005;86:S27-33.
Greiner D, Ochsendorf FR, Milbradt R. Vitiligo therapy with phenylalanine/UVA. Catamnestic studies after five years. Hautarzt. 1994;45:460-3.
Dell'Anna ML, Mastrofrancesco A, Sala R et al. Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial. Clin Exp Dermatol. 2007;32:631-6.
Maresca V, Roccella M, Roccella F et al. Increased sensitivity to peroxidative agents as a possible pathogenic factor of melanocyte damage in vitiligo. J Invest Dermatol. 1997;109:310-3.
Schallreuter KU, Wood JM, Lemke KR, Levenig C. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. Dermatology. 1995;190:223-9.
Shaker OG, El-Tahlawi SM. Is there a relationship between homocysteine and vitiligo? A pilot study. Br J Dermatol. 2008;159:720-4.
Singh S, Singh U, Pandey SS. Increased level of serum homocysteine in vitiligo. J Clin Lab Anal. 2011;25:110-2.
Steiner D, Bedin V, Moraes MB et al. Vitiligo. An Bras Dermatol. 2004;79:333-51.
Al'Abadie MS, Kent GG, Gawkrodger DJ. The relationship between stress and the onset and exacerbation of psoriasis and other skin conditions. Br J Dermatol. 1994;130:199-203.
Papadopoulos L, Bor R, Legg C, Hawk JL. Impact of life events on the onset of vitiligo in adults: preliminary evidence for a psychological dimension in aetiology. Clin Exp Dermatol. 1998;23:243-8.
